A Study of Baricitinib in Participants With Rheumatoid Arthritis

Description

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).

Conditions

Rheumatoid Arthritis

Talk to us

Study Overview

On this page

Study Details

Study overview

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis

A Study of Baricitinib in Participants With Rheumatoid Arthritis

Condition
Rheumatoid Arthritis
Intervention / Treatment

-

Contacts and Locations

Flagstaff

Arizona Arthritis & Rheumatology Associates, Flagstaff, Arizona, United States, 86001

Gilbert

Arizona Arthritis & Rheumatology Associates, P. C., Gilbert, Arizona, United States, 85704

Glendale

Arizona Arthritis & Rheumatology Research, Glendale, Arizona, United States, 85306

Mesa

Arizona Arthritis & Rheumatology Associates, P. C., Mesa, Arizona, United States, 85210

Peoria

Sun Valley Arthritis Center, LTD, Peoria, Arizona, United States, 85381

Phoenix

Arizona Arthritis & Rheumatology Research, Phoenix, Arizona, United States, 85032

Phoenix

Arizona Arthritis & Rheumatology Associates, P. C., Phoenix, Arizona, United States, 85037

Sun City

Arizona Arthritis & Rheumatology Associates, P. C., Sun City, Arizona, United States, 85351

Tucson

Arizona Arthritis & Rheumatology Associates, P. C., Tucson, Arizona, United States, 85704

Jonesboro

Arthritis and Rheumatism Associates, Jonesboro, Arkansas, United States, 72401

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must have at least one of the following characteristics:
  • * Documented evidence of a VTE prior to this study
  • * At least 60 years of age
  • * A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or
  • * Age 50 to less than 60 years and BMI 25 to less than 30 kg/m²
  • * Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic)
  • * Participant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was:
  • * discontinued for IR (lack or loss of efficacy) for RA, or
  • * discontinued for intolerance (AE) when used for any indication
  • * Participants must not be pregnant or breastfeeding
  • * Participants must not have had more than one VTE
  • * Participants must not have cancer
  • * Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness
  • * Participants must not have had a live vaccine within four weeks of study start
  • * Participants must not have participated in any other clinical trial within four weeks of study start
  • * Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2026-02